Literature DB >> 20430655

A patient with DiGeorge syndrome with spina bifida and sacral myelomeningocele, who developed both hypocalcemia-induced seizure and epilepsy.

Hiroyuki Kinoshita1, Takashi Kokudo, Takafumi Ide, Yasushi Kondo, Tokuo Mori, Yasunobu Homma, Mutsuko Yasuda, Junji Tomiyama, Fumiatsu Yakushiji.   

Abstract

DiGeorge syndrome - a component of the 22q11 deletion syndrome - causes a disturbance in cervical neural crest migration that results in parathyroid hypoplasia. Patients can develop hypocalcemia-induced seizures. Spina bifida is caused by failure of neurulation, including a disturbance in the adhesion processes at the neurula stage. Spina bifida has been reported as a risk factor for epilepsy. We report, for the first time, the case of a patient with DiGeorge syndrome with spina bifida and sacral myelomeningocele, who developed both hypocalcemia-induced seizures and epilepsy. The patient had spina bifida and sacral myelomeningocele at birth. At the age of 13 years, he experienced a seizure for the first time. At this time, the calcium concentration was normal. An electroencephalogram (EEG) proved that the seizure was due to epilepsy. Antiepileptic medications controlled the seizure. At the age of 29, the patient's calcium concentration began to reduce. At the age of 40, hypocalcemia-induced seizure occurred. At this time, the calcium concentration was 5.5mg/dL (reference range, 8.7-10.1mg/dL). The level of intact parathyroid hormone (PTH) was 6 pg/mL (reference range, 10-65 pg/mL). Chromosomal and genetic examinations revealed a deletion of TUP-like enhancer of split gene 1 (tuple1)-the diagnostic marker of DiGeorge syndrome. Many patients with DiGeorge syndrome have cardiac anomalies; however, our patient had none. We propose that the association among DiGeorge syndrome, spina bifida, epilepsy, cardiac anomaly, 22q11, tuple1, and microdeletion inheritance should be clarified for appropriate diagnosis and treatment. Copyright 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20430655     DOI: 10.1016/j.seizure.2010.04.005

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  8 in total

Review 1.  Brain extracellular space, hyaluronan, and the prevention of epileptic seizures.

Authors:  Katherine L Perkins; Amaia M Arranz; Yu Yamaguchi; Sabina Hrabetova
Journal:  Rev Neurosci       Date:  2017-11-27       Impact factor: 4.353

2.  Neural tube defects and atypical deletion on 22q11.2.

Authors:  Chiara Leoni; David A Stevenson; Katherine B Geiersbach; Christian N Paxton; Bryan L Krock; Rong Mao; Alan F Rope
Journal:  Am J Med Genet A       Date:  2014-08-13       Impact factor: 2.802

3.  Neuropsychiatric aspects of 22q11.2 deletion syndrome: considerations in the prenatal setting.

Authors:  Anne S Bassett; Gregory Costain; Christian R Marshall
Journal:  Prenat Diagn       Date:  2016-11-14       Impact factor: 3.050

Review 4.  Primary immunodeficiency diseases associated with neurologic manifestations.

Authors:  Soodabeh Fazeli Dehkordy; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2011-10-26       Impact factor: 8.542

Review 5.  Hypocalcemia-induced seizure: demystifying the calcium paradox.

Authors:  Pengcheng Han; Bradley J Trinidad; Jiong Shi
Journal:  ASN Neuro       Date:  2015-03-24       Impact factor: 4.146

6.  An Adult Case of Chromosome 22q11.2 Deletion Syndrome Associated with a High-positioned Right Aortic Arch.

Authors:  Yoichi Hoshino; Moriya Machida; Shun-Ichi Shimano; Teizo Taya
Journal:  Intern Med       Date:  2017-04-01       Impact factor: 1.271

7.  DiGeorge Syndrome with Sacral Myelomeningocele and Epilepsy.

Authors:  Gülsüm Alkan; Melike Keser Emiroglu; Ayse Kartal
Journal:  J Pediatr Neurosci       Date:  2017 Oct-Dec

Review 8.  Neurological Manifestations of Primary Immunodeficiencies.

Authors:  Zahra Chavoshzadeh; Amir Hashemitari; Sepideh Darougar
Journal:  Iran J Child Neurol       Date:  2018
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.